Company intelligence / Profile preview
ForDoz Pharma
East Windsor, New Jersey, United Statesfordozpharma.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
ForDoz Pharma received FDA approval for its first product, doxorubicin hydrochloride liposomal injection, in July 2024 for ovarian cancer and AIDS-related Kaposi’s sarcoma. The product was launched in the US market in August via Lupin Pharmaceuticals as distributor. The company has a broad pipeline of generic and innovative complex injectable products leveraging proprietary particle-based drug delivery technologies.
- Therapeutic areas
- Oncology
- Modalities
- Liposome-based drug delivery (Liposomal injectables)MicrospheresNanosuspensionsMicellesMicrocrystal-suspensionsSmall molecule (as in doxorubicin)Nanoparticle (as a platform technology)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Lupin Pharmaceuticals Inc. – distribution partner for lead product in the US market
Beyond the preview
Go deeper on ForDoz Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ForDoz Pharma.